Curigliano Giuseppe (Giuseppe Curigliano, G Curigliano)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 187

Top Venues

NPJ breast cancer

Cancers

The oncologist

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Mariia Ivanova, Carlo Pescia, Dario Trapani, Konstantinos Venetis, Chiara Frascarelli, Eltjona Mane, Giulia Cursano, Elham Sajjadi, Cristian Scatena, Bruna Cerbelli, Giulia d'Amati, Francesca Maria Porta, Elena Guerini-Rocco, Carmen Criscitiello, Curigliano Giuseppe, Nicola Fusco
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence. Cancers 16 (11) (2024)
Pier Paolo M Berton Giachetti, Curigliano Giuseppe
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option? Nature reviews. Clinical oncology 21 (3) (2024)
Ilenia Migliaccio, Dario Romagnoli, Francesca Galardi, Francesca De Luca, Chiara Biagioni, Curigliano Giuseppe, Carmen Criscitiello, Alessandro Marco Minisini, Erica Moretti, Emanuela Risi, Cristina Guarducci, Agostina Nardone, Laura Biganzoli, Matteo Benelli, Luca Malorni
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial. JCO precision oncology 8 (2024)
Ilenia Migliaccio, Dario Romagnoli, Francesca Galardi, Francesca De Luca, Chiara Biagioni, Curigliano Giuseppe, Carmen Criscitiello, Alessandro Marco Minisini, Erica Moretti, Emanuela Risi, Cristina Guarducci, Agostina Nardone, Laura Biganzoli, Matteo Benelli, Luca Malorni
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial. JCO precision oncology 8 (2024)
Carmine Valenza, Dario Trapani, Sibylle Loibl, Stephen K L Chia, Harold J Burstein, Curigliano Giuseppe
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Carmen Belli, Elisabetta Setola, Gabriella Parma, Nicola Fusco, Massimo Barberis, Elena Guerini Rocco, Antonio Marra, Nicoletta Colombo, Curigliano Giuseppe
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The oncologist 29 (7) (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (5) (2024)
Liliana Ascione, Lorenzo Guidi, Ajay Prakash, Dario Trapani, Patricia LoRusso, Emil Lou, Curigliano Giuseppe
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 44 (3) (2024)
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf, Tonia Parker, Tari A King, Elizabeth A Mittendorf, Curigliano Giuseppe, Melissa E Hughes, Daniel G Stover, Sara M Tolaney, Lachelle Dawn Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter Grant Miller, Heather A Parsons
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Hesham Elghazaly, Hamdy A Azim, Hope S Rugo, David Cameron, Sandra M Swain, Curigliano Giuseppe, Nadia Harbeck, Debu Tripathy, Banu K Arun, Matti Aapro, Martine Piccart, Fatima Cardoso, Joseph Gligorov, Hagar I Elghazawy, Nagi S El Saghir, Frederique Penault-Llorca, Edith A Perez, Philip Poortmans, Hany Abdelaziz, Heba M El-Zawahry, Loay Kassem, Mohamed Sabry, Giuseppe Viale, Sana Al-Sukhun, Neven Gado, Jessica W T Leung, Lobna Ezz Elarab, Maria João Cardoso, Khaled Abdel Karim, Meteb Foheidi, Merit M Elmaadawy, PierFranco Conte, Ashraf S M Selim, Alaa Kandil, Rasha M Kamal, Ruslan M Paltuev, Valentina Guarneri, Omalkhair Abulkhair, Omar Zakaria, Mehra Golshan, Roberto Orecchia, Manal ElMahdy, Ahmed M Abdel-Aziz, Nermean Bahie Eldin
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 130 (19) (2024)
Carmen Belli, Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Raimondo Scalia, Anna Diana, Jessica Orefice, Liliana Ascione, Gloria Pellizzari, Nicola Fusco, Massimo Barberis, Bruno Daniele, Elena Guerini-Rocco, Curigliano Giuseppe
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. The oncologist 29 (8) (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Francesco Schettini, Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio di Meglio, Rinat Bernstein Molho, Sabine C Linn, Katarzyna Pogoda, Estela Carrasco, Kevin Punie, Elisa Agostinetto, Nerea Lopetegui Lia, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Marion Acheritogaray, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal Garza, De Marchis Laura, Fabio Puglisi, Leonor Vasconcelos de Matos, Monica Mariño, Luis Teixeira, Rossella Graffeo, Alessia Rognone, Alessandra Chirco, Nicoleta Antone, Yara G Abdou, Maximilian Marhold, Ivana Božović-Spasojević, Cortes Salgado Alfonso, Luca Carmisciano, Marco Bruzzone, Curigliano Giuseppe, Aleix Prat, Matteo Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Curigliano Giuseppe
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The oncologist 29 (6) (2024)
Konstantinos Venetis, Carlo Pescia, Giulia Cursano, Chiara Frascarelli, Eltjona Mane, Elisa De Camilli, Elisabetta Munzone, Silvia Dellapasqua, Carmen Criscitiello, Curigliano Giuseppe, Elena Guerini Rocco, Nicola Fusco
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy. International journal of molecular sciences 25 (11) (2024)
Konstantinos Venetis, Carlo Pescia, Giulia Cursano, Chiara Frascarelli, Eltjona Mane, Elisa De Camilli, Elisabetta Munzone, Silvia Dellapasqua, Carmen Criscitiello, Curigliano Giuseppe, Elena Guerini Rocco, Nicola Fusco
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy. International journal of molecular sciences 25 (11) (2024)
Liliana Ascione, Lorenzo Guidi, Ajay Prakash, Dario Trapani, Patricia LoRusso, Emil Lou, Curigliano Giuseppe
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 44 (3) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Carmen Belli, Elisabetta Setola, Gabriella Parma, Nicola Fusco, Massimo Barberis, Elena Guerini Rocco, Antonio Marra, Nicoletta Colombo, Curigliano Giuseppe
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The oncologist 29 (7) (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (5) (2024)
Konstantinos Venetis, Carlo Pescia, Giulia Cursano, Chiara Frascarelli, Eltjona Mane, Elisa De Camilli, Elisabetta Munzone, Silvia Dellapasqua, Carmen Criscitiello, Curigliano Giuseppe, Elena Guerini Rocco, Nicola Fusco
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy. International journal of molecular sciences 25 (11) (2024)
Elisabetta Munzone, Antonio Marra, Federico Comotto, Lorenzo Guercio, Claudia Anna Sangalli, Martina Lo Cascio, Eleonora Pagan, Davide Sangalli, Ilaria Bigoni, Francesca Maria Porta, Marianna D'Ercole, Fabiana Ritorti, Vincenzo Bagnardi, Nicola Fusco, Curigliano Giuseppe
Development and Validation of a Natural Language Processing Algorithm for Extracting Clinical and Pathological Features of Breast Cancer From Pathology Reports. JCO clinical cancer informatics 8 (2024)
Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Carmen Belli, Elisabetta Setola, Gabriella Parma, Nicola Fusco, Massimo Barberis, Elena Guerini Rocco, Antonio Marra, Nicoletta Colombo, Curigliano Giuseppe
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The oncologist 29 (7) (2024)
Jalissa Katrini, Laura Boldrini, Celeste Santoro, Carmine Valenza, Dario Trapani, Curigliano Giuseppe
Biomarkers for Antibody-Drug Conjugates in Solid Tumors. Molecular cancer therapeutics 23 (4) (2024)
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Curigliano Giuseppe, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Berton Giacchetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Curigliano Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers 16 (2) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Curigliano Giuseppe
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The oncologist 29 (6) (2024)
Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Carmen Belli, Elisabetta Setola, Gabriella Parma, Nicola Fusco, Massimo Barberis, Elena Guerini Rocco, Antonio Marra, Nicoletta Colombo, Curigliano Giuseppe
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The oncologist 29 (7) (2024)
Mariia Ivanova, Carlo Pescia, Dario Trapani, Konstantinos Venetis, Chiara Frascarelli, Eltjona Mane, Giulia Cursano, Elham Sajjadi, Cristian Scatena, Bruna Cerbelli, Giulia d'Amati, Francesca Maria Porta, Elena Guerini-Rocco, Carmen Criscitiello, Curigliano Giuseppe, Nicola Fusco
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence. Cancers 16 (11) (2024)
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Curigliano Giuseppe
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The oncologist 29 (6) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Jalissa Katrini, Laura Boldrini, Celeste Santoro, Carmine Valenza, Dario Trapani, Curigliano Giuseppe
Biomarkers for antibody-drug conjugates in solid tumors. Molecular cancer therapeutics (2024)
Hesham Elghazaly, Hamdy A Azim, Hope S Rugo, David Cameron, Sandra M Swain, Curigliano Giuseppe, Nadia Harbeck, Debu Tripathy, Banu K Arun, Matti Aapro, Martine Piccart, Fatima Cardoso, Joseph Gligorov, Hagar I Elghazawy, Nagi S El Saghir, Frederique Penault-Llorca, Edith A Perez, Philip Poortmans, Hany Abdelaziz, Heba M El-Zawahry, Loay Kassem, Mohamed Sabry, Giuseppe Viale, Sana Al-Sukhun, Neven Gado, Jessica W T Leung, Lobna Ezz Elarab, Maria João Cardoso, Khaled Abdel Karim, Meteb Foheidi, Merit M Elmaadawy, PierFranco Conte, Ashraf S M Selim, Alaa Kandil, Rasha M Kamal, Ruslan M Paltuev, Valentina Guarneri, Omalkhair Abulkhair, Omar Zakaria, Mehra Golshan, Roberto Orecchia, Manal ElMahdy, Ahmed M Abdel-Aziz, Nermean Bahie Eldin
Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer (2024)
Ilenia Migliaccio, Dario Romagnoli, Francesca Galardi, Francesca De Luca, Chiara Biagioni, Curigliano Giuseppe, Carmen Criscitiello, Alessandro Marco Minisini, Erica Moretti, Emanuela Risi, Cristina Guarducci, Agostina Nardone, Laura Biganzoli, Matteo Benelli, Luca Malorni
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial. JCO precision oncology 8 (2024)
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Curigliano Giuseppe, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Curigliano Giuseppe
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The oncologist 29 (6) (2024)
Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H Barrios, Joyce A O'Shaughnessy, Hans Wildiers, Jean-Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joo Hyuk Sohn, Seock-Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Curigliano Giuseppe, null null
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. The New England journal of medicine (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf, Tonia Parker, Tari A King, Elizabeth A Mittendorf, Curigliano Giuseppe, Melissa E Hughes, Daniel G Stover, Sara M Tolaney, Lachelle Dawn Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter Grant Miller, Heather A Parsons
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Francesco Schettini, Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio di Meglio, Rinat Bernstein Molho, Sabine C Linn, Katarzyna Pogoda, Estela Carrasco, Kevin Punie, Elisa Agostinetto, Nerea Lopetegui Lia, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Marion Acheritogaray, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal Garza, De Marchis Laura, Fabio Puglisi, Leonor Vasconcelos de Matos, Monica Mariño, Luis Teixeira, Rossella Graffeo, Alessia Rognone, Alessandra Chirco, Nicoleta Antone, Yara G Abdou, Maximilian Marhold, Ivana Božović-Spasojević, Cortes Salgado Alfonso, Luca Carmisciano, Marco Bruzzone, Curigliano Giuseppe, Aleix Prat, Matteo Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer 130 (16) (2024)
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Berton Giacchetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Curigliano Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers 16 (2) (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-Deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine 30 (8) (2024)
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Berton Giacchetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Curigliano Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers 16 (2) (2024)
Javier Cortes, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Curigliano Giuseppe, Sung-Bae Kim, Joanne Wing Yan Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Paige Hamilton
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature medicine (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Pier Paolo M Berton Giachetti, Curigliano Giuseppe
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option? Nature reviews. Clinical oncology 21 (3) (2024)
Isabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, Judy C Boughey, Curigliano Giuseppe, Sue Friedman, Wendy K Kohlmann, Allison W Kurian, Christine Laronga, Filipa C Lynce, Barbara S Norquist, Jennifer K Plichta, Patricia Rodriguez, Payal Deepak Shah, Marc Tischkowitz, Marie Wood, Siddhartha Yadav, Katherine Yao, Mark E Robson
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (5) (2024)
Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Carmen Belli, Elisabetta Setola, Gabriella Parma, Nicola Fusco, Massimo Barberis, Elena Guerini Rocco, Antonio Marra, Nicoletta Colombo, Curigliano Giuseppe
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The oncologist (2024)
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Curigliano Giuseppe, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D'Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ breast cancer 10 (1) (2024)
Carmine Valenza, Dario Trapani, Sibylle Loibl, Stephen K L Chia, Harold J Burstein, Curigliano Giuseppe
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Khalid El Bairi, Dario Trapani, Sara Jamil Nidhamalddin, Shah Zeb Khan, Arman Reza Chowdhury, Csongor György Lengyel, Sadaqat Hussain, Baker Shalal Habeeb, Angelica Petrillo, Nabil Elhadi Omar, Sara Cecilia Altuna, Fahmi Usman Seid, Essam Elfaham, Andreas Seeber, Felipe Santa Rosa Roitberg, Alan Burguete-Torres, Safa El Kefi, Nazik Hammad, Miriam Mutebi, Ouissam Al Jarroudi, Nadia El Kadmiri, Curigliano Giuseppe, Said Afqir
Global Landscape of the Attack of Predatory Journals in Oncology. JCO global oncology 10 (2024)
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione, Gloria Pellizzari, Celeste Santoro, Valeria Fuorivia, Massimo Barberis, Nicola Fusco, Elena Guerini Rocco, Curigliano Giuseppe
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology. The oncologist (2024)
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf, Tonia Parker, Tari A King, Elizabeth A Mittendorf, Curigliano Giuseppe, Melissa E Hughes, Daniel G Stover, Sara M Tolaney, Lachelle Dawn Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter Grant Miller, Heather A Parsons
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs 33 (8) (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs (2024)
Carmen Belli, Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Raimondo Scalia, Anna Diana, Jessica Orefice, Liliana Ascione, Gloria Pellizzari, Nicola Fusco, Massimo Barberis, Bruno Daniele, Elena Guerini-Rocco, Curigliano Giuseppe
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. The oncologist 29 (8) (2024)
Carmen Belli, Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Raimondo Scalia, Anna Diana, Jessica Orefice, Liliana Ascione, Gloria Pellizzari, Nicola Fusco, Massimo Barberis, Bruno Daniele, Elena Guerini-Rocco, Curigliano Giuseppe
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers. The oncologist (2024)
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Curigliano Giuseppe, Carmen Criscitiello, Nicola Fusco
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management. Genes 14 (6) (2023)
Laura Gilardi, Lighea Simona Airò Farulla, Curigliano Giuseppe, Giovanni Corso, Maria Cristina Leonardi, Francesco Ceci
FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma. Biomedicines 11 (5) (2023)
Luca Licata, Giulia Viale, Mario Giuliano, Curigliano Giuseppe, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Lorenzo Guidi, Carmine Valenza, Dario Trapani, Curigliano Giuseppe
Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target? Expert opinion on biological therapy (2023)
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Curigliano Giuseppe
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15 (4) (2023)
Curigliano Giuseppe, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A Gelmon, Erica Stringer-Reasor, Ulka N Vaishampayan, Mark Ross Middleton, Anthony J Olszanski, Hope S Rugo, Kenneth A Kern, Nuzhat Pathan, Rachelle Perea, Kristen J Pierce, Sarah C Mutka, Zev A Wainberg
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British journal of cancer (2023)
Luca Boscolo Bielo, Stefano Natangelo, Jalissa Katrini, Dario Trapani, Curigliano Giuseppe
A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs. Expert opinion on drug metabolism & toxicology (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Gabriele Antonarelli, Valentina Pieri, Francesca Maria Porta, Nicola Fusco, Gaetano Finocchiaro, Curigliano Giuseppe, Carmen Criscitiello
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation. Cells 12 (6) (2023)
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Curigliano Giuseppe
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15 (4) (2023)
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Curigliano Giuseppe, Carmen Criscitiello, Nicola Fusco
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management. Genes 14 (6) (2023)
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Curigliano Giuseppe, Carmen Criscitiello, Nicola Fusco
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management. Genes 14 (6) (2023)
Edoardo Crimini, Giulia Tini, Paolo Tarantino, Liliana Ascione, Matteo Repetto, Paolo Beria, Alberto Ranghiero, Antonio Marra, Carmen Belli, Carmen Criscitiello, Angela Esposito, Elena Guerini Rocco, Massimo C P Barberis, Luca Mazzarella, Curigliano Giuseppe
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience. The oncologist (2023)
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Curigliano Giuseppe
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers 15 (4) (2023)
Eleonora Nicolò, Paolo Tarantino, Oriana D'Ecclesiis, Gabriele Antonarelli, Luca Boscolo Bielo, Antonio Marra, Sara Gandini, Edoardo Crimini, Federica Giugliano, Paola Zagami, Chiara Corti, Dario Trapani, Stefania Morganti, Carmen Criscitiello, Marzia Locatelli, Carmen Belli, Angela Esposito, Ida Minchella, Massimo Cristofanilli, Sara M Tolaney, Curigliano Giuseppe
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents. The oncologist (2023)
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Curigliano Giuseppe, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer 9 (1) (2023)
Gabriele Antonarelli, Valentina Pieri, Francesca Maria Porta, Nicola Fusco, Gaetano Finocchiaro, Curigliano Giuseppe, Carmen Criscitiello
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation. Cells 12 (6) (2023)
Luca Boscolo Bielo, Dario Trapani, Curigliano Giuseppe
Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer. Expert opinion on pharmacotherapy (2023)
Mariia Ivanova, Francesca Maria Porta, Marianna D'Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini Rocco, Curigliano Giuseppe, Giuseppe Viale, Nicola Fusco
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Archiv : an international journal of pathology (2023)
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Curigliano Giuseppe, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ breast cancer 9 (1) (2023)
Curigliano Giuseppe, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Andrea Botticelli, Roberta Caputo, Simone Scagnoli, Simona Pisegna, Michelino De Laurentiis, Curigliano Giuseppe, Matteo Lambertini, Francesco Pantano, Antonella Palazzo, Ida Paris, Claudio Vernieri, Beatrice Tedesco, Marianna Giampaglia, Michela Palleschi, Zelmira Ballatore, Daniele Alesini, Giuliana D'Auria, Agnese Fabbri, Luigi Rossi, Annarita Verrazzo, Roberta Scafetta, Daniele Marinelli, Caterina Sposetti, Vittoria Barberi, Lidia Strigari, Paolo Marchetti, Daniele Santini, Alessandra Fabi
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. The oncologist (2023)
Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Curigliano Giuseppe
The emerging role of PI3K inhibitors for solid tumour treatment and beyond. British journal of cancer (2023)
Curigliano Giuseppe, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. NPJ breast cancer 9 (1) (2023)
Liliana Ascione, Edoardo Crimini, Dario Trapani, Antonio Marra, Carmen Criscitiello, Curigliano Giuseppe
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability. The oncologist (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Carmine Valenza, Beatrice Taurelli Salimbeni, Celeste Santoro, Dario Trapani, Gabriele Antonarelli, Curigliano Giuseppe
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers 15 (3) (2023)
Chiara Corti, Federica Giugliano, Eleonora Nicolò, Paolo Tarantino, Carmen Criscitiello, Curigliano Giuseppe
HER2-Low Breast Cancer: a New Subtype? Current treatment options in oncology (2023)
Pier Paolo M Berton Giachetti, Curigliano Giuseppe
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option? Nature reviews. Clinical oncology (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, Victor Moreno, Yeon Hee Park, Sun Young Rha, Pavani Chalasani, Wei Zhong, Diansong Zhou, Steven R Pirie-Shepherd, Abraham Cf Leung, Curigliano Giuseppe
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study. Molecular cancer therapeutics (2023)
Federica Giugliano, Ambra Carnevale Schianca, Chiara Corti, Mariia Ivanova, Nadia Bianco, Silvia Dellapasqua, Carmen Criscitiello, Nicola Fusco, Curigliano Giuseppe, Elisabetta Munzone
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. Cancers 15 (5) (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)

Curigliano Giuseppe.css-eqlu8i{font-size:small;padding-left:4px;} (Giuseppe Curigliano, G Curigliano)

Publication Activity (10 Years)

Top Topics

Top Venues

Curigliano Giuseppe (Giuseppe Curigliano, G Curigliano)